Clinical Research Directory
Browse clinical research sites, groups, and studies.
Ca-Mg Butyrate in GWI
Sponsor: VA Office of Research and Development
Summary
The primary objective of this clinical trial is to determine if treatment with Butyrate formulation that consists of butyric acid as calcium and magnesium derivatives (Ca-Mg Butyrate) improves the physical function of men and women Veterans suffering from Gulf War Illness (GWI). The primary outcome measure is a change from baseline on the Short Form Health Survey 36-item (VSF-36), with respect to physical functioning and symptoms. The secondary outcome will focus on the drug's role in (a) restoring gut microbiome and virome, (b) decreasing gastrointestinal disturbances (constipation, diarrhea, pain), (c) decreasing chronic fatigue, (d) decreasing systemic inflammation, and (e) a decrease in cognitive deficits.
Official title: Microbiome Targeted Oral Butyrate Therapy in Gulf War Multisymptom Illness
Key Details
Gender
All
Age Range
40 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
120
Start Date
2024-01-15
Completion Date
2027-03-31
Last Updated
2025-10-31
Healthy Volunteers
No
Interventions
Cal-Mag Butyrate
Supplements
Placebo
Only Cal-Mag but no Butyric acid
Locations (3)
VA Long Beach Healthcare System, Long Beach, CA
Long Beach, California, United States
Miami VA Healthcare System, Miami, FL
Miami, Florida, United States
VA Salt Lake City Health Care System, Salt Lake City, UT
Salt Lake City, Utah, United States